B8FK
Biofrontera AG
Stock XETRA – Stock Market Prices, News & Analysis
Entreprise biopharmaceutique développant et commercialisant des thérapies pour le traitement du cancer de la peau et d'autres maladies dermatologiques.
Biofrontera AG
B8FK
Entreprise biopharmaceutique développant et commercialisant des thérapies pour le traitement du cancer de la peau et d'autres maladies dermatologiques.
Price history of Biofrontera AG
Price history of Biofrontera AG
Performance & Momentum
Strategic Analysis
Biofrontera AG • 2026
Biofrontera AG positions itself as a specialist player in the development and commercialization of innovative treatments for skin cancer and dermatological diseases, leveraging its targeted biotechnology platform. Its pharmaceutical niche, combining dermatologic oncology and dermatology products, gives it a differentiated profile in the healthcare sector in Germany.
- Strong specialization in dermatological and oncological therapies, creating an entry barrier.
- Product portfolio focused on unmet medical needs in a niche segment.
- Exposure to a growing sector with steady demand for innovative treatments.
- A stock performance history that has been particularly volatile and sharply negative over the long term.
- No recent announcements or visible catalysts to support the valuation.
Recent momentum is moderately positive, suggesting a renewed level of interest after a long period of underperformance. However, the disconnect between this momentum and the multi-year trend calls for caution, and investors will need to monitor clinical and commercial developments to confirm a sustainable turnaround.
Similar stocks to Biofrontera AG
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
